Objective To study the changes of parameters of platelet (Pt), mean platelet volume( MPV ), platelet constrict volume ( PCT ), and platelet distribution width (PDW) in child idiopathic thrombocytopenic purpura (ITP) before and after anti-virus treatment. Methods Pt,MPV,PCT and PDW were determined in 110 cases with child ITP, including slight group ( 16 cases), medium group(38 cases ), serious group (30 cases) and more serious group (26 cases) before and after treatment with anti-virus as well as in 110 normal controls with XT-1800i auto blood cell analysis instrument. Results There were significant differences on MPV, PDW and PCT between the patients of slight group and medium group, and so on medium group and serious group, serious group and more serious group (P<0.01 ).There was significant difference on PCT between the patients of slight group and more serious group (P<0.01 ). Before treatment, in the patients the MPV, PDW were significantly higher and the Pt, PCT were significantly lower than those in the controls and after treatment (P<0.01 ). After treatment,the levels of Pt and PCT were lower in the patients than those in the controls (P<0.05), but , MPV, PDW were no difference. Conclusion Dynamic changes of parameter of platelet could reflect the progress of ITP and could guide clinical treatment.

Objective:To study the adverse reactions (ADRs) of recombinant human erythropoietin (rHuEPO) to provide refer-ence for clinical rational and safe medication. Methods:ADRs induced by rHuEPO reported at home and abroad were collected and analyzed in respects of age,gender,original illness, occurrence time, clinical manifestations and the results. Results: After the re-trieval,there were 149 cases of rHuEPO-induced ADRs with the damage of cardio vascular system, hematologic system, skin and its appendents accounting for 43.4%,20.8% and 12.7%,respectively. The top three main clinical manifestations of rHuEPO drug reac-tions were hypertension,pure red-cell aplastic anemia (PRCA) and hyperkalemia. The occurrence time should be paid particular at-tention in 5-12 weeks after the administration (43.0%). Conclusion:Physicians should be aware of rHuEPO-induced ADRs (espe-cially the occurrence time),pay attention to patients' medication education and avoid serious adverse reactions.